146 related articles for article (PubMed ID: 18648960)
1. Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post-treatment.
Brouwer CA; Gietema JA; van den Berg MP; Bink-Boelkens MT; Elzenga NJ; Haaksma J; Kamps WA; Vonk JM; Postma A
J Cancer Surviv; 2007 Dec; 1(4):255-60. PubMed ID: 18648960
[TBL] [Abstract][Full Text] [Related]
2. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
4. Myocardial 2D Strain During Long-Term (>5 Years) Follow-Up of Childhood Survivors of Acute Lymphoblastic Leukemia Treated With Anthracyclines.
Pourier MS; Mavinkurve-Groothuis AMC; Dull MM; Weijers G; Loonen J; Bellersen L; de Korte CL; Kapusta L
Am J Cardiol; 2020 Jul; 127():163-168. PubMed ID: 32444028
[TBL] [Abstract][Full Text] [Related]
5. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
6. Impaired exercise capacity and left ventricular function in long-term adult survivors of childhood acute lymphoblastic leukemia.
Christiansen JR; Kanellopoulos A; Lund MB; Massey R; Dalen H; Kiserud CE; Ruud E; Aakhus S
Pediatr Blood Cancer; 2015 Aug; 62(8):1437-43. PubMed ID: 25832752
[TBL] [Abstract][Full Text] [Related]
7. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.
Rammeloo LA; Postma A; Sobotka-Plojhar MA; Bink-Boelkens MT; Berg A; Veerman AJ; Kamps WA
Med Pediatr Oncol; 2000 Jul; 35(1):13-9. PubMed ID: 10881002
[TBL] [Abstract][Full Text] [Related]
8. Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.
Shimomura Y; Baba R; Watanabe A; Horikoshi Y; Asami K; Hyakuna N; Iwai A; Matsushita T; Yamaji K; Hori T; Tsurusawa M;
Pediatr Blood Cancer; 2011 Sep; 57(3):461-6. PubMed ID: 21298773
[TBL] [Abstract][Full Text] [Related]
9. A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.
Messinger Y; Uckun FM
Leuk Lymphoma; 1999 Aug; 34(5-6):415-32. PubMed ID: 10492065
[TBL] [Abstract][Full Text] [Related]
10. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
[TBL] [Abstract][Full Text] [Related]
11. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.
Hudson MM; Rai SN; Nunez C; Merchant TE; Marina NM; Zalamea N; Cox C; Phipps S; Pompeu R; Rosenthal D
J Clin Oncol; 2007 Aug; 25(24):3635-43. PubMed ID: 17704413
[TBL] [Abstract][Full Text] [Related]
14. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H; Nielsen G
Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828
[TBL] [Abstract][Full Text] [Related]
15. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
16. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
[TBL] [Abstract][Full Text] [Related]
17. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
[TBL] [Abstract][Full Text] [Related]
18. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity: A Major Setback in Childhood Leukemia Treatment.
Lazăr DR; Farcaş AD; Blag C; Neaga A; Zdrenghea MT; Căinap C; Lazăr FL; Stef A; Căinap SS
Dis Markers; 2021; 2021():8828410. PubMed ID: 33505537
[TBL] [Abstract][Full Text] [Related]
20. Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood.
Prestor VV; Rakovec P; Kozelj M; Jereb B
Pediatr Hematol Oncol; 2000; 17(7):527-40. PubMed ID: 11033728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
